LAVAL, QC, Oct. 20, 2017 /PRNewswire/ - Prometic
Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today
announces in vivo data from compounds PBI-4050 and PBI-4547 for the
prevention and treatment of liver diseases, and associated
metabolic syndrome are being presented in three poster sessions at
AASLD (The Liver MeetingĀ®) in Washington,
D.C. from Oct. 20-24,
2017.
"We are excited by the implications of our data and the promise
of our candidates PBI-4050 and PBI-4547 for the treatment and
prevention of liver diseases," said Pierre
Laurin, president and chief executive officer, Prometic.
"These results in varying mouse models of liver disease demonstrate
Prometic's ability to target multiple indications, including
hepatic fibrosis, metabolic syndrome, and non-alcoholic fatty liver
disease."
PBI-4050, a novel first-in-class oral compound, also is
currently in clinical phase II study for diabetic patients with
metabolic syndrome.
About PBI-4050 data:
The first poster, entitled: PBI-4050 Inhibits Hepatic Stellate
Cell Proliferation and Activation Via AMPK, and Improves Hepatic
Fibrosis in CCL4-Induced Liver Injury Model, examined PBI-4050's
ability to decrease hepatic stellate cell (HSC) activation via AMPK
and prevent fibrosis in mice. Results of the study showed PBI-4050
is a potential novel therapy for hepatic fibrosis.
Presentation details: Publication # 392, October 20, 2017 from 8:00
AM - 5:30 PM, Session: Basic Fibrosis Research and Stellate
Cell Biology, Washington
Convention Center, Hall D
The second poster, entitled: PBI-4050 Reduces Liver Damage and
Fibrosis in a High-Fat Diet Mouse Model of Obesity and Metabolic
Syndrome, demonstrated improvements in glucose metabolism, serum
triglycerides, hepatic steatosis and ballooning in the liver in a
mouse model of non-alcoholic fatty liver disease (NAFLD) after
dosing with PBI-4050. These data suggest an important clinical
application of PBI-4050 in the prevention of liver
diseases.
Presentation details: Publication # 2016, October 23, 2017 from 8:00
AM to 5:30 PM
Session: Steatohepatitis: Experimental, Washington Convention Center, Hall D
About PBI-4547 data:
The third poster, entitled: PBI-4547 Reverses Liver Steatosis
and Fibrosis, and Improves Metabolic Syndrome in ob/ob Mice,
presented results from ob/ob mice orally dosed with PBI-4547,
demonstrating reduction in blood levels of glucose, cholesterol,
and triglyceride, in fibrosis/cell infiltration, in liver steatosis
and hepatocellular ballooning. These data suggest PBI-4547 is a
potential novel therapy for NAFLD, obesity, and metabolic
syndrome.
Presentation details: Publication # 2017, October 23, 2017 from 8:00
AM to 5:30 PM,
Session: Steatohepatitis: Experimental, Location: Washington Convention Center, Hall D
About AASLD
The AASLD conference is an annual conference that highlights the
latest liver diseases research and discusses treatment outcomes
with physicians, researchers and healthcare practitioners involved
in the science and practice of hepatology.
About Prometic Life Sciences Inc.
Prometic Life
Sciences Inc. (www.prometic.com) is a long-established
biopharmaceutical company with globally recognized expertise in
bioseparations, plasma-derived therapeutics and small-molecule drug
development. Prometic is active in developing its own novel
small-molecule therapeutic products targeting unmet medical needs
in the field of fibrosis, cancer and autoimmune
diseases/inflammation. A number of plasma-derived and small
molecule products are under development for orphan drug
indications. Prometic also offers its state-of-the-art technologies
for large-scale purification of biologics, drug development,
proteomics and the elimination of pathogens to a growing base of
industry leaders and uses its own affinity technology that provides
for highly efficient extraction and purification of therapeutic
proteins from human plasma in order to develop best-in-class
therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities
in the UK, the U.S. and Canada, manufacturing facilities in the UK
and commercial activities in the U.S., Canada, Europe and Asia.
Forward Looking
Statements
This press release contains forward-looking statements about
Prometic's objectives, strategies and businesses that involve risks
and uncertainties. These statements are "forward-looking" because
they are based on our current expectations about the markets we
operate in and on various estimates and assumptions. Actual events
or results may differ materially from those anticipated in these
forward-looking statements if known or unknown risks affect our
business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited
to, Prometic's ability to develop, manufacture, and successfully
commercialize value-added pharmaceutical products, the availability
of funds and resources to pursue R&D projects, the successful
and timely completion of clinical studies, the ability of Prometic
to take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or
results to materially differ from our current expectations in
Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and
Uncertainties related to Prometic's business". As a result,
we cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by
applicable securities laws and regulations. All amounts are
in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.